Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Complement system biomarkers in epilepsy

Kopczynska, Maja, Zelek, Wioleta, Vespa, Simone, Touchard, Samuel, Wardle, Mark, Loveless, Samantha ORCID:, Thomas, Rhys H., Hamandi, Khalid and Morgan, B. Paul ORCID: 2018. Complement system biomarkers in epilepsy. Seizure - European Journal of Epilepsy 60 , pp. 1-7. 10.1016/j.seizure.2018.05.016

[thumbnail of Epilepsy Paper May 2018.pdf]
PDF - Accepted Post-Print Version
Download (405kB) | Preview


Purpose To explore whether complement dysregulation occurs in a routinely recruited clinical cohort of epilepsy patients, and whether complement biomarkers have potential to be used as markers of disease severity and seizure control. Methods Plasma samples from 157 epilepsy cases (106 with focal seizures, 46 generalised seizures, 5 unclassified) and 54 controls were analysed. Concentrations of 10 complement analytes (C1q, C3, C4, factor B [FB], terminal complement complex [TCC], iC3b, factor H [FH], Clusterin [Clu], Properdin, C1 Inhibitor [C1Inh] plus C-reactive protein [CRP]) were measured using enzyme linked immunosorbent assay (ELISA). Univariate and multivariate statistical analysis were used to test whether combinations of complement analytes were predictive of epilepsy diagnoses and seizure occurrence. Correlation between number and type of anti-epileptic drugs (AED) and complement analytes was also performed. Results We found: 1) significant differences between all epilepsy patients and controls for TCC (p < 0.01) and FH (p < 0.01) after performing univariate analysis. 2) multivariate analysis combining six analytes (C3, C4, Properdin, FH, C1Inh, Clu) to give a predictive value (area under the curve) of 0.80 for differentiating epilepsy from controls. 3) significant differences in complement levels between patients with controlled seizures (n = 65) in comparison with uncontrolled seizures (n = 87). Levels of iC3b, Properdin and Clu were decreased and levels of C4 were increased in patients with uncontrolled seizures. 4) no correlation was found between the level of complement biomarkers and the number of AEDs taken, but an association between some analyte levels and drug therapy was seen in patients taking sodium valproate, clobazam, and perampanel. Conclusion This study adds to evidence implicating complement in pathogenesis of epilepsy and may allow the development of better therapeutics and prognostic markers in the future. Replication in a larger sample set is needed to validate the findings of the study.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Cardiff University Brain Research Imaging Centre (CUBRIC)
Publisher: Elsevier
ISSN: 1059-1311
Date of First Compliant Deposit: 3 July 2018
Date of Acceptance: 22 May 2018
Last Modified: 24 Jun 2024 17:01

Citation Data

Cited 20 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics